Premarket Notification [510(k)] Summary Trilogy Mx Radiotherapy Treatment System

NE NOV 30 2009

The following information is provided following the format of 21 CFR 807.92.

Submitter's Name:

Varian Medical Systems, Inc. 3100 Hansen Way e-110 Palo Alto, CA 94304

Contact Name: Vy Tran Phone: 650/424.5731 Fax: 650/842.5040

Date: 16th September 2009

Proprietary Name:

Trilogy Mx™

Classification Name:

Medical charged-particle radiation therapy system

21 CFR 892.5050, Class II

Product Code: 90 IYE

Common/Usual Name:

Trilogy Mx Radiotherapy Delivery System

Predicate Devices:

Trilogy Radiotherapy System and Accessories:

K072916, K042720, K063270, K081036, K003636, K071992,

K050442

Device Description:

The Trilogy Mx[™] Radiotherapy Delivery System is a medical linear accelerator that integrates the previously cleared Trilogy Radiotherapy system and associated accessories into a single device.

The system consists of two major components, a photon, electron, and diagnostic kV X-ray radiation beam-producing component that is installed in a radiation-shielded vault and a control console area

located outside the treatment room.

Statement of Intended Use

The Trilogy Mx[™] system is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.


Statement of Indications for Use:

The Trilogy Mx[™] system is intended to provide stereotactic radiosurgery

and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.

Technological Characteristics:

Refer to the Substantial Equivalence Comparison Chart



Food and Drug Administration 10903 New Hampshire Avenue Document Control Room – WO66-G609 Silver Spring, MD 20993-0002

NOV 3 0 2009

Ms. Vy Tran VP Corporate Regulatory Affairs Varian Medical Systems, Inc. 3100 Hansen Way PALO ALTO CA 94304-1038

Re: K092871

Trade/Device Name: Trilogy Mx[™]

Regulation Number: 21 CFR §892.5050

Regulation Name: Medical charged-particle radiation therapy system

Regulatory Class: II Product Code: IYE

Dated: September 16, 2009 Received: September 18, 2009

Dear Ms. Tran:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 801); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Singerely yours.

Janine M. Morris`

Acting Director, Division of Reproductive,
Abdominal, and Radiological Devices

and readionoglour

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosure

Indications for Use

5 To(k) Number (ii known). <u>Koszaz I</u>
Device Name: Trilogy Mx
Indications For Use:
Trilogy Mx is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.
Prescription Use X AND/OR Over-The-Counter Use (21 CFR 801 Subpart D) (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
1 Agum Nh
(Division of Reproductive, Abdominal,
and Radiological Devices Page 1 of1